
    
      The study will enroll up to 40 subjects, with up to 5 dose escalating cohorts of 8 patients
      enrolled in a 3:1 ratio. Subjects will receive either itolizumab or placebo administered
      subcutaneously every two weeks (over 8 weeks) for a total of 5 doses with 4 weeks of
      follow-up.
    
  